Results 231 to 240 of about 66,449 (275)

Hydrogel-mediated mitochondrial reprogramming for inducing cell death: a novel approach to overcoming gemcitabine resistance in pancreatic ductal adenocarcinoma. [PDF]

Mater Today Bio
Zhao Q, Liu S, Bi T, Wang T, Chen L, Huang J, Yang X, Dai X, Liu Z, Sun Q.   +9 more
europepmc   +1 more source

TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism. [PDF]

Adv Sci (Weinh)
Fan X, Dai Y, Mo C, Li H, Luan X, Wang B, Yang J, Jiao G, Lu X, Chen Z, Liao Y, Qu L, Yang H, Lou C, Liu C, Li Z.   +15 more
europepmc   +1 more source

CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance. [PDF]

Cell Death Dis
Zheng D, Deng Y, Deng L, He Z, Sun X, Gong Y, Shi B, Lu D, Yu C.   +8 more
europepmc   +1 more source

Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. [PDF]

Acta Pharmacol Sin
Li BR, Wang T, Hu HF, Wu D, Zhou CJ, Ji SR, Zhuo QF, Li Z, Wang ZL, Fan GX, Jing DS, Yu CY, Qin Y, Chen XM, Xu JF, Xu XW.   +15 more
europepmc   +1 more source

Cancer-associated fibroblast-derived COL17A1 promotes gemcitabine resistance and tumorigenesis in pancreatic cancer cells by interacting with ACTN4. [PDF]

Discov Oncol
Shi R, Zhang N, Li H, Zhong H, Zhong C, Du W, Yang X.   +6 more
europepmc   +1 more source

α-Asarone attenuates tumor-associated macrophages-induced gemcitabine resistance in pancreatic carcinoma via the transforming growth factor-beta 1/growth factor independent 1 axis. [PDF]

Anticancer Drugs
Yu J, Xue Y, Gao Z, Hu L, Liu X, He X, Wang X.   +6 more
europepmc   +1 more source

Non-glycanated ΔDCN isoform in muscle invasive bladder cancer mediates cancer stemness and gemcitabine resistance. [PDF]

Cell Oncol (Dordr)
Wu N, Wang J, Fan M, Liang Y, Wei Qi X, Deng F, Zeng F.   +6 more
europepmc   +1 more source

[Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression. [PDF]

Oncol Lett
Guo H, Liu F, Yang S, Xue T.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates, 2015
Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The disappointing 5-year survival rate of below 5% stems from drug resistance to all known therapies, as well as from disease presentation at a late stage when PDA is already metastatic. Gemcitabine has been the cornerstone of PDA treatment in all stages of the disease for
Yoav, Binenbaum, Shorook, Na'ara, Ziv, Gil   +2 more
openaire   +4 more sources

Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

Drug Resistance Updates, 2002
The inherent or induced resistance of tumors to cytostatic agents is a major clinical problem. In this review, we summarize the pre-clinical mechanisms of acquired and inherent resistance to the fluorinated deoxycytidine analog gemcitabine (2',2'-difluorodeoxycytidine, dFdC, Gemzar((R))), which has proven activity in non-small cell lung carcinoma ...
Andries M, Bergman, Herbert M, Pinedo, Godefridus J, Peters   +2 more
openaire   +4 more sources